Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants

Summary

The primary objective is to evaluate in a double-blinded (neither physician nor participant knows the treatment that the participant receives), fashion the taste of different JNJ-53718678 oral liquid formulations as compared to the reference formulation (JNJ-53718678, 10 milligram/milliliter oral solution without sweetener/flavor).

Conditions

• Healthy

Interventions

DRUG

Formulation A

Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.

DRUG

Formulation B

10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.

DRUG

Formulation C

10 mg/mL oral solution containing 10 mg/mL sucralose.

DRUG

Formulation D

10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.

DRUG

Formulation E

10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.

DRUG

Formulation F

10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.

DRUG

Formulation M1

Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation M2

Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation M3

Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation N1

Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation N2

Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

DRUG

Formulation N3

Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).

Sponsors & Collaborators

• Janssen Sciences Ireland UC

  lead INDUSTRY

Principal Investigators

• Janssen Sciences Ireland UC Clinical Trial · Janssen Sciences Ireland UC

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2015-03-04

Primary Completion

2015-04-24

Completion

2015-04-24

Countries

• United Kingdom

Study Locations